STOCK TITAN

PROCEPT BioRobotics Corporation (PRCT) Stock News, Aug 2022-Feb 2023

PRCT NASDAQ

PROCEPT BioRobotics Corporation reports developments in surgical robotics for urology, centered on its AQUABEAM and HYDROS Robotic Systems and Aquablation therapy for lower urinary tract symptoms caused by benign prostatic hyperplasia. Company news commonly covers financial results, system sales and procedure trends, commercial execution, pricing and inventory commentary, and investment in its BPH platform technology.

Updates also include product clearances such as FirstAssist AI software, international launch activity for HYDROS, clinical evidence and guideline recognition for Aquablation therapy, investor presentations, and research activity including the WATER IV prostate cancer trial.

Rhea-AI Summary

PROCEPT BioRobotics Corporation (Nasdaq: PRCT) reported significant financial growth for 2022, with total revenue reaching $75.0 million, a 118% increase from 2021. In Q4 2022 alone, revenue was $23.8 million, marking a 135% rise year-over-year. System and rental revenue for the U.S. hit $10.4 million, up 109%, while handpiece and consumable revenue soared by 202%. Despite a net loss of $28.2 million for the quarter, the company projects $125 million in revenue for 2023, reflecting a 67% growth forecast. Key factors driving growth include expansion in the sales team and increased market interest.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.97%
Tags
-
Rhea-AI Summary

PROCEPT BioRobotics Corporation (Nasdaq: PRCT) has announced that its management will present at the 43rd Annual Cowen Health Care Conference in Boston on March 7, 2023, at 12:50 p.m. Eastern Time. Interested parties can access a live webcast and an archived recording on the company’s website for at least 90 days following the event.

PROCEPT is recognized for its AquaBeam Robotic System, aimed at enhancing minimally invasive surgery for benign prostatic hyperplasia (BPH). Currently, BPH affects around 40 million men in the U.S., and PROCEPT's innovative Aquablation therapy is supported by extensive clinical evidence, including nine studies and over 100 peer-reviewed publications.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.14%
Tags
conferences
-
Rhea-AI Summary

PROCEPT BioRobotics plans to report its fourth quarter and fiscal year 2022 financial results on February 28, 2023. Preliminary unaudited revenue for Q4 2022 is projected between $23.6 million and $23.8 million, significantly up from $10.1 million in Q4 2021. Total revenue for fiscal year 2022 is expected to be around $74.8 million to $75 million, reflecting a 117% growth year-over-year. The company emphasizes its commitment to advancing patient care in urology through innovative surgical solutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.23%
Tags
Rhea-AI Summary

PROCEPT BioRobotics Corporation (Nasdaq: PRCT) announced its participation in the 41st Annual J.P. Morgan Healthcare Conference, scheduled for January 10, 2023, at 9:45 a.m. Pacific Time. The event will feature a presentation by the company's management team. Interested parties can access a live webcast and an archived recording through the company’s website.

PROCEPT BioRobotics focuses on innovating surgical robotics for urology, specifically addressing benign prostatic hyperplasia (BPH) through its AquaBeam Robotic System, which is backed by extensive clinical evidence.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.14%
Tags
conferences
-
Rhea-AI Summary

PROCEPT BioRobotics (Nasdaq: PRCT) reported a 135% increase in total revenue for Q3 2022, totaling $20.3 million compared to the same period last year. U.S. system revenue rose 95% to $9.8 million, while handpiece revenue surged 267% to $8.0 million. The company raised its 2022 revenue guidance to approximately $72.5 million, a 110% growth over 2021. However, net loss widened to $22.6 million and operating expenses increased to $32.3 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.43%
Tags
-
Rhea-AI Summary

PROCEPT BioRobotics Corporation (Nasdaq: PRCT) will release its third quarter financial results on November 3, 2022, after the market closes. A conference call with management will follow at 1:30 p.m. Pacific Time. Investors can join via webcast or phone. The company is focused on surgical robotics, specifically addressing benign prostatic hyperplasia (BPH) through the AquaBeam Robotic System, which has shown significant clinical evidence in improving patient outcomes. Information on the event will be accessible on their website and archived recordings will be available for 90 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.67%
Tags
conferences earnings
Rhea-AI Summary

PROCEPT BioRobotics Corporation (Nasdaq: PRCT) announced a new five-year $52 million loan agreement with CIBC Innovation Banking to enhance its financial position. This loan will refinance an existing $50 million debt, allowing for an interest-only payment period of up to 48 months and reducing annual interest expenses by approximately $2.8 million. CFO Kevin Waters emphasized that this arrangement supports the company’s long-term growth strategy and provides financial flexibility. PROCEPT specializes in surgical robotics, focusing on treating benign prostatic hyperplasia.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.97%
Tags
none
-
Rhea-AI Summary

PROCEPT BioRobotics (Nasdaq: PRCT) and Providence have formed a multi-system national contract for the acquisition of AquaBeam Robotic Systems, enhancing patient care in urology. As of June 30, 2022, Providence had seven AquaBeam systems installed in California and Texas. Doctor Richard Shapiro emphasized that Aquablation therapy offers long-term symptom relief for men with benign prostatic hyperplasia. PROCEPT aims to accelerate adoption of Aquablation therapy, prioritizing patient safety and effectiveness by using advanced robotic technology for precise prostate treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.84%
Tags
none
-
Rhea-AI Summary

PROCEPT BioRobotics Corporation (Nasdaq: PRCT) has announced its participation in the 2022 Wells Fargo healthcare conference, with management scheduled to present on September 7 at 9:10 a.m. Eastern Time. The event will be available via live webcast on the company’s website, offering an archived recording for at least 90 days post-event. PROCEPT focuses on advancing patient care through innovative surgical robotics, particularly with its AquaBeam Robotic System aimed at treating benign prostatic hyperplasia, impacting about 40 million men in the U.S.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.31%
Tags
conferences
Rhea-AI Summary

PROCEPT BioRobotics Corporation (Nasdaq: PRCT) reported Q2 2022 results showing a 97% year-over-year revenue increase to $16.7 million, driven by strong U.S. sales. System revenue reached $8.5 million (+79%), while handpiece sales surged 246% to $5.7 million. The company raised its 2022 revenue guidance to $66-$68 million (91%-97% growth). However, net loss grew to $19.2 million from $14.6 million in the prior year. Operating expenses increased to $26.4 million, reflecting expansion efforts. Cash reserves stand at $269.8 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.56%
Tags

FAQ

What is the current stock price of PROCEPT BioRobotics (PRCT)?

PROCEPT BioRobotics (PRCT) last closed at $23.54.

What is the market cap of PROCEPT BioRobotics (PRCT)?

The market cap of PROCEPT BioRobotics (PRCT) is approximately $1.4B.